Your browser doesn't support javascript.
loading
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.
Norhammar, Anna; Bodegard, Johan; Eriksson, Jan W; Haller, Hermann; Linssen, Gerard C M; Banerjee, Amitava; Karasik, Avraham; Mamouris, Pavlos; Tangri, Navdeep; Taveira-Gomes, Tiago; Maggioni, Aldo P; Botana, Manuel; Thuresson, Marcus; Okami, Suguru; Yajima, Toshitaka; Kadowaki, Takashi; Birkeland, Kåre I.
Afiliación
  • Norhammar A; Cardiology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden.
  • Bodegard J; Capio St Görans Hospital, Stockholm, Sweden.
  • Eriksson JW; AstraZeneca, Oslo, Norway.
  • Haller H; Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.
  • Linssen GCM; Division of Nephrology, Hannover Medical School, Hannover, Germany.
  • Banerjee A; Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, The Netherlands.
  • Karasik A; Institute of Health Informatics, University College London, London, UK.
  • Mamouris P; Department of Cardiology, University College London Hospitals, London, UK.
  • Tangri N; Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Taveira-Gomes T; Academic Center for General Practice, KU Leuven, Leuven, Belgium.
  • Maggioni AP; Department of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Canada.
  • Botana M; Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Thuresson M; ANMCO Research Centre, Florence, Italy.
  • Okami S; Maria Cecilia Hospital, GVM Care and Research, Cotignola, Italy.
  • Yajima T; Endocrinology Service, Lucus Augusti University Hospital, Lugo, Spain.
  • Kadowaki T; Statisticon AB, Uppsala, Sweden.
  • Birkeland KI; AstraZeneca, Osaka, Japan.
Diabetes Obes Metab ; 24(7): 1277-1287, 2022 07.
Article en En | MEDLINE | ID: mdl-35322567
AIM: To examine how the development of cardiovascular and renal disease (CVRD) translates to hospital healthcare costs in individuals with type 2 diabetes (T2D) initially free from CVRD. METHODS: Data were obtained from the digital healthcare systems of 12 nations using a prespecified protocol. A fixed country-specific index date of 1 January was chosen to secure sufficient cohort disease history and maximal follow-up, varying between each nation from 2006 to 2017. At index, all individuals were free from any diagnoses of CVRD (including heart failure [HF], chronic kidney disease [CKD], coronary ischaemic disease, stroke, myocardial infarction [MI], or peripheral artery disease [PAD]). Outcomes during follow-up were hospital visits for CKD, HF, MI, stroke, and PAD. Hospital healthcare costs obtained from six countries, representing 68% of the total study population, were cumulatively summarized for CVRD events occurring during follow-up. RESULTS: In total, 1.2 million CVRD-free individuals with T2D were identified and followed for 4.5 years (mean), that is, 4.9 million patient-years. The proportion of individuals indexed before 2010 was 18% (n = 207 137); 2010-2015, 31% (361 175); and after 2015, 52% (609 095). Overall, 184 420 (15.7%) developed CVRD, of which cardiorenal disease was most frequently the first disease to develop (59.7%), consisting of 23.0% HF and 36.7% CKD, and more common than stroke (16.9%), MI (13.7%), and PAD (9.7%). The total cumulative cost for CVRD was US$1 billion, of which 59.0% was attributed to cardiorenal disease, 3-, 5-, and 6-fold times greater than the costs for stroke, MI, and PAD, respectively. CONCLUSION: Across all nations, HF or CKD was the most frequent CVRD manifestation to develop in a low-risk population with T2D, accounting for the highest proportion of hospital healthcare costs. These novel findings highlight the importance of cardiorenal awareness when planning healthcare.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Accidente Cerebrovascular / Diabetes Mellitus Tipo 2 / Insuficiencia Renal Crónica / Insuficiencia Cardíaca / Infarto del Miocardio Tipo de estudio: Guideline / Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2022 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Accidente Cerebrovascular / Diabetes Mellitus Tipo 2 / Insuficiencia Renal Crónica / Insuficiencia Cardíaca / Infarto del Miocardio Tipo de estudio: Guideline / Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2022 Tipo del documento: Article País de afiliación: Suecia